Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | PRKDC | P78527 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 8/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | FGR | P09769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969401 | 0.93 | TGFBR1 (0.44) | TGFBR1PIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2960168 | 0.89 | PIK3CD (0.46) | TGFBR1PIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2967433 | 0.83 | PIK3CD (0.47) | TGFBR1PIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2956385 | 0.83 | KDR (0.51) | TGFBR1PIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2960164 | 0.82 | PIK3CD (0.46) | TGFBR1PIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2962359 | 0.79 | PIK3CD (0.44) | TGFBR1PIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2953986 | 0.78 | IGF1R (0.52) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2953705 | 0.78 | IGF1R (0.52) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2953703 | 0.78 | IGF1R (0.52) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2961978 | 0.78 | SRC (0.59) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | claimed |
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | TGFBR1 4446/4885PIK3CD 264/4885PRKDC 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.